4D Molecular Therapeutics Secures Funding, Advances Gene Therapy Pipeline for AMD, DME & CF

Irvine, CA – November 10, 2025 – 4D Molecular Therapeutics (4DMT) is bolstering its position as a leader in gene therapy with a recent wave of funding and encouraging clinical trial data across its core programs targeting age-related macular degeneration (AMD), diabetic macular edema (DME), and cystic fibrosis (CF). A newly secured equity offering, coupled with a significant investment from the Cystic Fibrosis Foundation, will power the company’s pipeline through critical clinical milestones and pave the way for potential commercialization.

Funding Fuels Expansion & Clinical Progress

4DMT recently completed a successful equity offering, generating approximately $93 million in net proceeds. This, combined with an upfront payment and anticipated cost-sharing from a strategic partnership with Otsuka Pharmaceutical, and a further $11 million investment from the Cystic Fibrosis Foundation, extends the company’s cash runway into the second half of 2028. This financial stability allows 4DMT to focus on advancing its lead programs through late-stage clinical trials and preparing for potential regulatory submissions.

“The successful equity offering and continued support from the CFF are strong validations of our platform and the potential of our gene therapy programs,” said a company spokesperson. “This funding provides us with the resources to execute on our strategic goals and bring transformative therapies to patients in need.”

Pioneering Gene Therapy for Ocular Diseases

4DMT’s lead programs focus on delivering a functional gene directly to the eye, offering a potentially durable and less invasive treatment option for AMD and DME. Recent data from ongoing Phase 3 trials of 4D-150 for both conditions demonstrate promising efficacy and safety profiles.

For AMD, the 4FRONT trial continues to enroll patients, and preliminary data suggest a dose-dependent improvement in visual acuity. The SPECTRA trial for DME, meanwhile, has demonstrated significant gains in visual acuity and a substantial reduction in the need for frequent injections. “The sustained improvement in visual acuity, coupled with the reduction in treatment burden, could significantly improve the quality of life for DME patients,” a source familiar with the trial data commented.

The company’s approach is generating considerable excitement in the ocular gene therapy space, where traditional treatments often require frequent injections and may not provide long-lasting relief. “4DMT’s technology has the potential to disrupt the current standard of care for both AMD and DME,” stated an industry analyst. “The ability to deliver a durable therapeutic effect with a single injection could be a game-changer.”

Addressing the Root Cause of Cystic Fibrosis

Beyond ocular diseases, 4DMT is making significant strides in developing a gene therapy for cystic fibrosis, a genetic disorder that affects the lungs and other organs. The company's 4D-710 program utilizes an inhaled AAV vector to deliver a functional copy of the CFTR gene directly to lung cells. The Cystic Fibrosis Foundation’s recent $11 million investment underscores the potential of this approach.

“This investment is a testament to the compelling preclinical and Phase 1 data we’ve generated with 4D-710,” explained a foundation spokesperson. “We believe this therapy has the potential to address the underlying cause of CF and improve lung function for patients regardless of their specific CFTR variant.”

Phase 2 clinical trials are currently underway, and initial data suggest that 4D-710 is well-tolerated and capable of delivering the CFTR gene to lung cells. The company is also exploring the possibility of redosing patients to maintain therapeutic benefits over the long term. “The ability to redose patients could be crucial for achieving sustained improvements in lung function,” commented a clinical trial investigator. “It's a significant advantage over some other gene therapy approaches.”

Navigating a Competitive Landscape

The gene therapy space is becoming increasingly competitive, with numerous companies vying to develop innovative treatments for a wide range of diseases. 4DMT distinguishes itself through its unique platform technology, which enables the efficient delivery of genes to target tissues. The company is also focused on developing therapies for diseases with significant unmet medical needs, such as AMD, DME, and CF.

However, several competitors are also active in these areas, including REGENXBIO, Atsena Therapeutics, and others. “The ocular gene therapy market is becoming crowded,” noted an industry analyst. “Companies will need to demonstrate clear clinical differentiation to succeed.”

Furthermore, challenges remain in scaling up manufacturing, navigating regulatory hurdles, and ensuring long-term safety and efficacy. 4DMT has assembled a strong team of scientists, clinicians, and regulatory experts to address these challenges and advance its pipeline towards commercialization.

Looking Ahead

4D Molecular Therapeutics is poised for significant growth in the coming years. With a strong financial foundation, a promising pipeline of gene therapies, and a dedicated team of experts, the company is well-positioned to become a leader in the rapidly evolving gene therapy landscape.

The next 12-18 months will be crucial as 4DMT continues to enroll patients in its Phase 3 trials, generate additional clinical data, and prepare for potential regulatory submissions. The company's success could have a profound impact on the lives of patients suffering from AMD, DME, cystic fibrosis, and other debilitating diseases. “We are committed to bringing innovative therapies to patients in need and improving their quality of life,” concluded a company representative. “We believe gene therapy has the potential to transform the treatment of many diseases, and we are excited to be at the forefront of this revolution.”